Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Razelle Kurzrock

ARID1A Alterations Function as a Biomarker for Longer Progression-Free Survival After Anti-Pd-1/Pd-L1 Immunotherapy

Journal for ImmunoTherapy of Cancer

English

Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

The Lancet Haematology

Hematology

2020

English

Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations

Cancer Research

Oncology

2014

English

NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies

Journal of the National Comprehensive Cancer Network : JNCCN

Medicine

Oncology

2014

English

Phase 1 Clinical Trials in 83 Patients With Pancreatic Cancer

English

GNAS, GNAQ, and GNA11 Alterations in Patients With Diverse Cancers

English

Cancer Research in the United States: A Critical Review of Current Status and Proposal for Alternative Models

English

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

English

Debunking the Delusion That Precision Oncology Is an Illusion

English

Real‐World Toxicity Experience With BRAF/MEK Inhibitors in Patients With Erdheim‐Chester Disease

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Razelle Kurzrock

ARID1A Alterations Function as a Biomarker for Longer Progression-Free Survival After Anti-Pd-1/Pd-L1 Immunotherapy

Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations

NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies

Phase 1 Clinical Trials in 83 Patients With Pancreatic Cancer

GNAS, GNAQ, and GNA11 Alterations in Patients With Diverse Cancers

Cancer Research in the United States: A Critical Review of Current Status and Proposal for Alternative Models

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Debunking the Delusion That Precision Oncology Is an Illusion

Real‐World Toxicity Experience With BRAF/MEK Inhibitors in Patients With Erdheim‐Chester Disease